Alliance Pharma (LSE:APH) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 16, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alliance Pharma's float shares is 0.00 Mil. Alliance Pharma's total shares outstanding is 540.40 Mil. Alliance Pharma's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alliance Pharma's Insider Ownership is 10.32%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alliance Pharma's Institutional Ownership is 25.00%.

Alliance Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Alliance Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	540.40
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).